help me find hte answef

[Guest guest]

Amy,

It doesn't make any difference how many vaccines a kid has to a

certain disease, if it's a live or a modified live vaccine they

shed. Also I believe that most live or modified live vaccines will

cover most mutated strains of a virus at least we know this to be

the case with Parvo and Distemper vaccines and I have no reason to

believe that it wouldn't be any different with human virus vaccines.

What she may fail to realize that if a child sero-converts after one

vaccine (that means the body is producing anti-bodies two weeks

after the vaccine is given) any more vaccinations for that virus

will not produce more anti-bodies, it will just replace what is

there.

What would happen if the medicos will start doing an anti-body titer

and yes I know it doesn't mean immunity to a disease, but what if

before any vaccine is given the child or infant shows an adequate

anti-body to that disease which they are testing for. Will they

still decide to give the vaccine just to make sure. It's still the

same thing just replacing one set of anti-bodies with another.

When breastfeeding, it's the same thing, but maternal anti-bodies

wane with the age of the infant as the infant's own immune system

starts to take over.

Jackie Noel

www.sagaciousairedales.com

www.sagaciousdogcountry.com

[Guest guest]

Amy, below is info with direct proof that vaccines are the cause of

this. Also, there are many links on our site that state that

polymorphism is caused by the vaccine. Especially Hib, Prevnar, and

Pertussis. Most of the info from this page.

http://users.adelphia.net/~cdc/VaccineInfo.htm

Have lots of fun with this. If you need any more help let me know.

Pediatrics. 1990 Apr;85(4 Pt 2):698-704. Related Articles, Links

Disease caused by Haemophilus influenzae type b in the immediate

period after homologous immunization: immunologic investigation.

Sood SK, Daum RS.

Department of Pediatrics, Tulane University School of Medicine, New

Orleans, Louisiana.

Several Haemophilus influenzae type b vaccines have been licensed and

recommended for administration to children in the United States.

These vaccines have consisted of purified polyribosylribitol-

phosphate (PRP), the capsular polysaccharide of H influenzae type b,

alone or covalently bound to one of several carrier proteins. Two of

these saccharide-protein conjugate vaccines are now licensed, a

polysaccharide-diphtheria toxoid conjugate (PRP-D) and an

oligosaccharide-mutant diphtheria toxin conjugate (HbOC). Two others,

a polysaccharide-Neisseria meningitidis outer membrane protein

conjugate (PRP-OMPC) and a polysaccharide-tetanus toxoid conjugate

(PRP-T), are currently in clinical trials. One concern with the use

of PRP vaccine was the suggestion that the incidence of invasive

disease caused by H influenzae type b in the immediate period after

immunization might be increased; this idea was supported by evidence

from several sources. In a case-control study of the efficacy of PRP

vaccine, Black et al found that 4 children were hospitalized for

invasive disease within 1 week of immunization, a rate of invasive

disease 6.4 times greater (95% confidence interval [CI], 2.1 to 19.2)

than the background rate in unvaccinated children. In Minnesota, the

relative risk for invasive disease in the first week after

immunization was 6.2 (95% CI, 0.6 to 45.9), and the results of a

study conducted by the Centers for Disease Control in six areas of

the United States revealed a 1.8-fold (95% CI, 0.3 to 10.2) increase

in the occurrence of invasive disease caused by H influenzae type b

in the first week after immunization.(ABSTRACT TRUNCATED AT 250 WORDS)

Publication Types:

Review

Review, Tutorial

PMID: 2107522 [PubMed - indexed for MEDLINE]

Harefuah. 1994 Oct;127(7-8):231-4, 287. Related Articles, Links

[Hemophilus influenzae meningitis despite vaccination]

[Article in Hebrew]

Jurgenson U, Asia A, Arav-Boger R.

Souraski--Tel Aviv Medical Center, Dana Children's Hospital.

An 18-month-old male previously vaccinated with 4 doses of HbOC

developed meningitis caused by Hemophilus influenzae type B.

Immunological status was normal and antibody titer to Hemophilus

influenzae type b was in the normal range for immunized children.

Meningitis due to this organism should be considered even in children

who are fully vaccinated.

Publication Types:

Case Reports

PMID: 7813948 [PubMed - indexed for MEDLINE]

J Infect Dis. 1988 Aug;158(2):343-8. Related Articles, Links

Spectrum of disease due to Haemophilus influenzae type b occurring in

vaccinated children.

Hiner EE, Frasch CE.

Division of Bacterial Products, Food and Drug Administration,

Bethesda, land 20892.

Haemophilus b polysaccharide vaccine was first licensed in the United

States in April 1985. Between May 1985 and September 1987, 228

reports of disease due to Haemophilus influenzae in vaccinated

children were submitted to the Food and Drug Administration, of which

216 were accepted for analysis. We compared the relative frequencies

of the different disease entities caused by H. influenzae type b

reported in vaccinated children with those reported in unvaccinated

children (greater than 1000 cases that occurred between 1973 and

1984, as reported in the literature). Over 90% of the vaccinated

children were greater than or equal to 24 mo of age. A higher

proportion of cases was reported to have occurred within the first

two months after vaccination, with 10 cases occurring within 72 h of

vaccination. Vaccination did not alter the expected frequencies of

the different clinical entities associated with invasive H.

influenzae disease. No estimates of clinical efficacy are possible

based on the adverse events submitted to the Food and Drug

Administration.

PMID: 3261314 [PubMed - indexed for MEDLINE]

J Infect Dis. 2000 Nov;182(5):1402-8. Epub 2000 Oct 09. Related

Articles, Links

Polymorphism in Bordetella pertussis pertactin and pertussis toxin

virulence factors in the United States, 1935-1999.

Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, Popovic T.

Division for Bacterial and Mycotic Diseases, Centers for Disease

Control and Prevention, Atlanta, GA 30333, USA. PCassiday@....

PCassiday@...

To elucidate the potential role of the etiologic agent in recent

increases of pertussis incidence in the United States, we studied the

polymorphism in pertactin and pertussis toxin, which are Bordetella

pertussis proteins important for pathogenesis and immunity. We

sequenced regions of their genes (prn and ptx) in 152 B. pertussis

strains isolated from 1935 through 1999 and identified 2 prn

sequences: prn1 (old), observed continuously since 1935, and prn2

(new), not recognized until 1981 but seen in 97% of tested isolates

in 1999. There were 3 ptx S1 subunit sequences: ptxS1D (old) was

identified in 3 strains (1935 and 1939); ptxS1B (old) represented 87%

of the strains recovered during 1935-1974; and ptxS1A (new) was the

most prevalent during 1975-1987 and 1989-1999 (64% and 78%,

respectively). Potential association between vaccination and the

observed shift from old to new types requires further study. Our

results provide the basis for prospectively monitoring for changes

among circulating B. pertussis that might have epidemiologic

relevance.

PMID: 11023463 [PubMed - indexed for MEDLINE]

J Infect Dis. 2003 Apr 15;187(8):1200-5. Epub 2003 Mar 26. Related

Articles, Links

Bordetella pertussis protein pertactin induces type-specific

antibodies: one possible explanation for the emergence of antigenic

variants?

He Q, Makinen J, Berbers G, Mooi FR, Viljanen MK, Arvilommi H,

Mertsola J.

Department of Human Microbial Ecology and Inflammation, National

Public Health Institute, Turku, Finland. qiushui.he@...

Divergence has been found between Bordetella pertussis vaccine

strains and circulating strains. Polymorphism in pertactin (Prn) is

essentially limited to region 1, which is made up of repeats. Today,

the 3 most prevalent Prn variants are Prn1-3. Vaccine strains produce

Prn1, whereas Prn2 is the predominant type found in circulating

strains. We investigated how variation in region 1 affects the

production of human serum antibodies. Individuals infected by Prn2

strains had significantly fewer antibodies to Prn1 did than those

infected by Prn3 strains and those immunized with a booster dose of

acellular vaccines containing Prn1. Moreover, in contrast to vaccine

recipients and subjects infected by Prn3 strains, individuals

infected by Prn2 strains had hardly any antibodies specific to the

variable region of Prn1. These results indicate that conformational

changes have occurred in the variable region of Prn, which may offer

a possible explanation for the emergence of Prn2 strains in certain

countries.

PMID: 12695998 [PubMed - indexed for MEDLINE]

Microbiology. 1999 Aug;145 ( Pt 8):2069-75. Related Articles, Links

Antigenic variants in Bordetella pertussis strains isolated from

vaccinated and unvaccinated children.

Mastrantonio P, Spigaglia P, van Oirschot H, van der Heide HG,

Heuvelman K, Stefanelli P, Mooi FR.

Department of Bacteriology and Medical Mycology, Istituto Superiore

di Sanita, Rome, Italy. pmastran@...

Bordetella pertussis shows polymorphism in two proteins, pertactin

(Prn) and the pertussis toxin (PT) S1 subunit, which are important

for immunity. A previous study has shown antigenic shifts in these

proteins in the Dutch B. pertussis population, and it was suggested

that these shifts were driven by vaccination. The recent Italian

clinical trial provided the opportunity to compare the frequencies of

Prn and PT S1 subunit variants in strains isolated from unvaccinated

children, and from children vaccinated with two acellular and one

whole-cell pertussis vaccine. Four Prn variants (Prn1, Prn2, Prn3 and

Prn5) were found in the 129 strains analysed. Prn1, Prn2 and Prn3

have been described previously, whereas Prn5 is a novel variant.

Prn1, Prn2, Prn3 and Prn5 were found in, respectively, 6, 41, 51 and

2% of the strains. The B. pertussis strains used to produce the

vaccines administered in the clinical trial were found to produce

Prn1, or a type which differed from Prn1 in one amino acid. The

frequency of the Prn1 variant was found to be lowest in the strains

isolated from vaccinated groups, suggesting that Prn1 strains are

more affected by vaccine-induced immunity than Prn2 and Prn3 strains.

Only one PT S1 type (S1A) was observed in the examined strains, which

was distinct from the types produced by the vaccine strains (S1B and

S1D). The S1A type also predominates in the Dutch B. pertussis

population. The genetic relationship among B. pertussis strains

analysed by IS1002-based DNA fingerprinting revealed that three

fingerprint types predominate, representing more than 70% of the

strains. Prn2 strains showed a greater variety of fingerprint types

compared to Prn3, suggesting that Prn3 has emerged more recently. The

results are discussed in the light of vaccine-driven evolution.

Publication Types:

Clinical Trial

Controlled Clinical Trial

PMID: 10463173 [PubMed - indexed for MEDLINE]

Microbiology. 2001 Nov;147(Pt 11):2885-95. Related Articles, Links

Role of the polymorphic region 1 of the Bordetella pertussis protein

pertactin in immunity.

King AJ, Berbers G, van Oirschot HF, Hoogerhout P, Knipping K, Mooi

FR.

Research Laboratory for Infectious Diseases, National Institute of

Public Health and the Environment, PO Box 1, 3720 BA Bilthoven, The

Netherlands.

In several countries pertussis is re-emerging, despite a high

vaccination coverage. It is suggested that antigenic divergence

between Bordetella pertussis vaccine strains and circulating strains,

in particular with respect to pertactin, has contributed to pertussis

re-emergence. Polymorphism in pertactin is essentially limited to

region 1, which is composed of repeats and is located adjacent to an

Arg-Gly-Asp motif implicated in adherence. Evidence is provided for

the immunological relevance of polymorphism in region 1. Region 1 was

found to contain a B-cell epitope recognized in both humans and mice.

Furthermore, variation in region 1 affected antibody binding and, in

a mouse respiratory infection model, the efficacy of a whole-cell

vaccine. Moreover, passive and active immunization indicated that

region 1 confers protective immunity. An mAb directed against a

linear conserved epitope conferred cross-immunity against isolates

with distinct pertactin variants. The results indicate an important

role of region 1 of pertactin in immunity.

PMID: 11700340 [PubMed - indexed for MEDLINE]

http://www.cdc.gov/ncidod/eid/vol7no3_supp/mooi.htm

In The Netherlands, as in many other western countries, pertussis

vaccines have been used extensively for more than 40 years.

Therefore, it is conceivable that vaccine-induced immunity has

affected the evolution of B. pertussis. Consistent with this notion,

pertussis has reemerged in The Netherlands, despite high vaccination

coverage. Further, a notable change in the population structure of B.

pertussis was observed in The Netherlands subsequent to the

introduction of vaccination in the 1950s. Finally, we observed

antigenic divergence between clinical isolates and vaccine strains,

in particular with respect to the surface-associated proteins

pertactin and pertussis toxin. Adaptation may have allowed B.

pertussis to remain endemic despite widespread vaccination and may

have contributed to the reemergence of pertussis in The Netherlands.

Pediatr Infect Dis J. 2004 Apr;23(4):307-13. Related Articles,

Links

Mucosal immune responses to capsular pneumococcal polysaccharides in

immunized preschool children and controls with similar nasal

pneumococcal colonization rates.

Zhang Q, Arnaoutakis K, Murdoch C, Lakshman R, Race G, Burkinshaw R,

Finn A.

Department of Clinical Sciences South Bristol, University of Bristol

Faculty of Medicine, UBHT Education Centre, Upper Maudlin Street,

Bristol BS2 8AE, UK.

BACKGROUND: Immunization with conjugate pneumococcal vaccines induces

significant primary and memory IgG anti-polysaccharide (PS) responses

in serum. It can also induce mucosal responses in infants especially

after a polysaccharide booster. However, it is unclear whether it can

prime for mucosal memory responses on nasal exposure to pneumococcus,

which may be important in protection against pneumococcal invasion

and/or carriage. METHOD: IgA and IgG to serotypes 4, 6B, 9V, 14, 18C,

19F and 23F (conjugate vaccine serotypes), 1 and 3 (nonvaccine

serotypes) capsular PS were measured by immunoassay in saliva from 2-

to 5-year-old children previously given three doses of 7-valent

pneumococcal conjugate vaccine in infancy, followed by 23-valent PS

vaccine at 13 months and from unvaccinated controls of similar age

and sex. Salivary antibody responses were analyzed in relation to

carriage of pneumococci assessed by bacterial culture of

nasopharyngeal swab samples collected in the summer and winter of the

year 2000. RESULTS: Rates of detectable IgG antibodies to all vaccine

serotypes except 23F were higher in subjects than in controls. No

such differences were observed for IgA antibodies except for serotype

6B. Nasal colonization rates were similar, and in both groups mucosal

IgA responses were more common and larger than IgG responses.

CONCLUSIONS: The mucosal anti-capsular IgA responses observed could

develop in response to colonization in preschool children, regardless

of vaccination status, and contribute to the falling carriage rates

observed with increasing age.

PMID: 15071283 [PubMed - in process]

J Infect Dis. 2003 May 15;187(10):1629-38. Epub 2003 Apr 30. Related

Articles, Links

Significant variation in serotype-specific immunogenicity of the

seven-valent Streptococcus pneumoniae capsular polysaccharide-CRM197

conjugate vaccine occurs despite vigorous T cell help induced by the

carrier protein.

Kamboj KK, Kirchner HL, Kimmel R, Greenspan NS, Schreiber JR.

Department of Pediatrics, Case Western Reserve University School of

Medicine, Rainbow Babies and Children's Hospital, Cleveland, Ohio

44106, USA.

Streptococcus pneumoniae capsular polysaccharides (PnPSs) induce

protective antibodies but are T cell-independent type 2 antigens and

are poorly immunogenic in infants. Conjugate vaccines of PnPSs linked

to proteins like cross-reactive material (CRM(197)) increase PS

antibody titer and elicit immunologic memory in infants. Despite

being linked to an identical carrier protein, each PS component of

the 7-valent PnPS-CRM(197) vaccine has different immunogenicity. To

determine whether variations in conjugate-induced memory T cell

responses or PnPS-specific antibody-secreting cells (ASCs) were

responsible for serotype-specific differences in immunogenicity,

adults were immunized with 7-valent PnPS-CRM(197), and antibody

titer, vaccine component-specific CD4(+) T cell recall response,

numbers of PnPS-specific ASCs, and cytokine production were measured.

PnPS-CRM(197) induced significantly different serotype-specific

antibody titers, despite vigorous T cell recall responses to all 7

vaccine components, and production of interleukin (IL)-2, IL-5, IL-6,

IL-10, and interferon-gamma. We conclude that PnPS-CRM(197) induces

variable serotype-specific antibody titers, despite induction of

comparable CRM(197)-specific memory T cell responses.

Publication Types:

Clinical Trial

PMID: 12721943 [PubMed - indexed for MEDLINE]

>

>

> I am having a current debate over vaccines and wish to post correct

info to

> this person I however now her state ment isnt exactly true but i

have been

> searching and cant find the info to support my answer to her can

any of you help

> me Please.

> thanks a bunch

>

> Amy

>

>

> Children who aren't fully vaccinated are at risk for diseases. With

that it

> can cause them to change strains and morph into other things for

which the

> vaccines we gave our children will not work for. Things like this

do happen. I

> would just rather not take that chance with my childrens life or

other childrens

> lives.

>

>

>

[Guest guest]

In my opinion, it's the people who haven't read any information on vaccines that

are the one's who seem to verbalize their scientific opinions the most. It is

my understanding, and someone correct me if I'm wrong, and according to my

chiropractor " vaccines simply do not work! " It's ironic that we assume that

just because we have a measurable antibody titer in our blood that we are immune

to the disease " I think the immune system is quite a complex system that we do

not fully understand and the idea that we can trick it into thinking it was

exposed to a disease when it really wasn't is a nice theory but to me hasn't

been proven adequately, not when there are documented cases of disease outbreaks

in 100% vaccinated populations! So what happened there, maybe it works for some

and not for others or they got a " bad batch " . Excuses are handly in times like

these.

Personally I wouldn't waste my time on this lady. Those are the one's that are

a waste of your breath! So did she give you some substantiation to this

" morphing " ? She says, " things like this do happen " Where? Where is this

documented? I think you need to ask this of this woman. Has anyone actually

taken an unvaccinated child or not fully vaccinated child and found that they

were responsible for a " morphed " version of a particular strain of disease?

And also that they infected a fully vaccinated child with that morphed

version??? I think she's off her crock! She would rather not take the chance

with her children's life. Oh Geesh!!! Well, why don't you tell her to pick up

the tele and call the local poison control center. Ask the person there to give

her the safe amount (according to the EPA) of aluminum, ethyl mercury,

formaldehyde, ethylene glycol, MSG just to name a few because you are going to

mix them into your child's food. Make sure you give the correct weight because

the vaccine manufacturers sure don't take that into account, its a same size

fits all! I can assure you and take into account that these toxins are injected

into our children's systems and are not going through the digestive process,

that you would probably be sitting in jail for poisoning your child, yet that's

exactly what the government does, poison's our children and the vaccine

companies are making billions from it and all of the other disorders they

create. I'm sorry but I'll take the disease anyday with consequences like

autism, add, asthma, diabetes! She won't go to your website because she's

right, she know's that she is right, those people don't look anything up and

they're always right!

Just my honest opinion.

Suzanne

Ohio